Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva
Abstract Fibrodysplasia ossificans progressive (FOP) is an ultra-rare genetic disorder that is caused by a mutation in the ACVR1 gene and provokes severe heterotopic ossification. Since flares of the disease are associated with inflammation, it is assumed that JAK inhibitors can control active FOP d...
| Автори: | , , , , , , , |
|---|---|
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
BMC
2023-08-01
|
| Серія: | Pediatric Rheumatology Online Journal |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1186/s12969-023-00856-1 |